Key result
Strong TLE1 expression (3+) was most frequently observed in poorly differentiated synovial sarcoma (75%, 18/24), but was also seen in other small round cell tumors.
Why the study?
The diagnostic utility of TLE1 for synovial sarcoma is limited by its expression in a broad range of tumor types, reducing specificity across small round cell tumors.
Observational (n=301)
No
TLE1 is highly expressed in poorly differentiated synovial sarcoma but lacks specificity, necessitating a panel of immunohistochemistry markers for accurate diagnosis of small round cell tumors.
Answers are grounded in this paper and cite their sources.
Proposed IHC algorithm may aid SRCT subtyping; leaves open prospective validation before clinical adoption.
Introduction. Small round cell tumors (SRCTs) represent a heterogeneous group of neoplasms with overlapping histological features but varying origins, prognoses, and treatments. TLE1 is a well-established marker for synovial sarcoma (SS). However, TLE1's diagnostic utility is limited by its expression in a broad range of tumor types, reducing its specificity for SS. This study explores TLE1 expression across SRCTs and proposes an immunohistochemical algorithm to enhance diagnostic accuracy. Methods. This retrospective, single-center observational study, conducted from 2019 to 2024, reviewed pathology records for SRCTs. TLE1 staining was evaluated using the immunoreactive score system, categorized as follows: 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong). Results. A total of 301 SRCTs were evaluated with diverse distribution: neuroendocrine neoplasms (21%, n = 63), extraskeletal Ewing sarcoma (15%, n = 45), lymphoblastic lymphoma (11%, n = 34), and poorly differentiated synovial sarcoma (PDSS) (8%, n = 24). TLE1 expression of 3 + was most frequently observed in PDSS (75%, 18/24). Other tumors with TLE1 3 + included extraskeletal Ewing sarcoma, extracutaneous malignant melanoma, neuroendocrine neoplasms, rhabdomyosarcoma, and endometrial stromal sarcoma. TLE1 2 + was noted in lymphoblastic lymphoma and desmoplastic SRCT, while TLE1 1 + was seen in some gastrointestinal stromal tumors. The remaining specimens were negative for TLE1. These findings led to a diagnostic framework for SRCTs based on TLE1 expression patterns. Conclusions. Although TLE1 is a key marker for SS, its expression in other tumors can present diagnostic challenges. Integrating clinical features, histological assessment, and a panel of immunohistochemistry markers is essential for accurate diagnosis and effective management of SRCTs.
No takes yet. Share an insight, caveat, or question.
Varma et al. (2025) conducted an observational in Small round cell tumors (SRCTs) (n=301). TLE1 expression was evaluated on TLE1 staining evaluated using the immunoreactive score system. Strong TLE1 expression (3+) was most frequently observed in poorly differentiated synovial sarcoma (75%, 18/24), but was also seen in other small round cell tumors.
Synapse has enriched 10 related papers. Consider them for comparative context: